CancerNCT05780957
Multi-Cancer Early Detection (MCED) of Firefighters
An observational study of Cancer, run by Vincere Cancer Center at 1 site in United States.
Trial summary
This study is an an observational prospective cohort research study to explore the performance of new blood and urine tests for the early detection of cancer among firefighters. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer
- What is being tested?
- MCED
- How many people
- 2,000 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Mar 2023to 31 Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Actively working firefighters of any adult age, any gender and any demographic group are eligible, as well as no limitations regarding general health status other than those specified in the protocol Eligibility Criteria.
Who may be able to join
- 18 years of age or older
- Currently employed as a firefighter, full-time or part-time
- Taking part in Vincere's First Responder Cancer Screening Program
- Able to donate blood and urine sample
- Able to provide informed consent to participate in the study
Who cannot join
- Deemed medically unfit for sample donation
- Personal history of cancer in the last 5 years (with the exception of non-melanoma skin cancer)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Vincere Cancer Center
Scottsdale, Arizona, 85260
Christine Lau, MD, (480)306-5390, drlau@vincerecancer.com
Vershalee Shukla, MD
About this study
This study is an an observational prospective cohort research study to explore the performance of new blood and urine tests for the early detection of cancer among firefighters.
- Conditions
- Cancer
- Being tested
- MCED
- Keywords
- Cancer, Multi-Cancer Early Detection, MCED
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MCEDOther
multi-cancer early detection (MCED) test
| Study group | Role | What they receive |
|---|---|---|
| Firefighters who receive multi-cancer early detection (MCED) test | Not described Receives: Other: MCED |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity, specificity, positive and negative predictive performance values (PPV and NPV) to detect cancer using Elypta's MCED test, as measured in plasma, in urine, and in plasma and urine combined
Measured: Up to 7 years
Sensitivity, specificity, positive and negative predictive performance values to detect cancer using Proteotype's MCED test, as measured in plasma.
Measured: Up to 2030
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2023
- Study start21 Mar 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vincere Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Elypta, Proteotype
- Responsible party
- Sponsor
- Investigators
- Vershalee Shukla, MD, Principal investigator, Vincere Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05780957
- Sponsor's protocol ID
- VCC-MCEDFF-001
- Status last verified
- Nov 2025
- First submitted
- 10 Mar 2023
- Last updated
- 5 Nov 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Cancer Early Detection (MCED) of Firefighters
- ClinicalTrials.gov ID
- NCT05780957
- Acronym / sponsor ID
- VCC-MCEDFF-001
- Conditions
- Cancer
- Keywords
- Cancer, Multi-Cancer Early Detection, MCED
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Vincere Cancer CenterUniversity, hospital or other
- Collaborators
- Elypta, Proteotype
- Study start
- 21 Mar 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 23 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is an an observational prospective cohort research study to explore the performance of new blood and urine tests for the early detection of cancer among firefighters.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Firefighters who receive multi-cancer early detection (MCED) test | – | Other: MCED |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Actively working firefighters of any adult age, any gender and any demographic group are eligible, as well as no limitations regarding general health status other than those specified in the protocol Eligibility Criteria.
Key inclusion criteria (5 listed)
- 18 years of age or older
- Currently employed as a firefighter, full-time or part-time
- Taking part in Vincere's First Responder Cancer Screening Program
- Able to donate blood and urine sample
- Able to provide informed consent to participate in the study
Key exclusion criteria (2 listed)
- Deemed medically unfit for sample donation
- Personal history of cancer in the last 5 years (with the exception of non-melanoma skin cancer)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MCEDmulti-cancer early detection (MCED) test | Other | Firefighters who receive multi-cancer early detection (MCED) test |
Primary outcome
Sensitivity, specificity, positive and negative predictive performance values (PPV and NPV) to detect cancer using Elypta's MCED test, as measured in plasma, in urine, and in plasma and urine combined
Time frame: Up to 7 years
Sensitivity, specificity, positive and negative predictive performance values to detect cancer using Proteotype's MCED test, as measured in plasma.
Time frame: Up to 2030
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2025.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vershalee Shukla, MD principal investigator
Vincere Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Vincere Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christine Lau, MD (480-306-5390, drlau@vincerecancer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity, specificity, positive and negative predictive performance values (PPV and NPV) to detect cancer using Elypta's MCED test, as measured in plasma, in urine, and in plasma and urine combined (time frame: Up to 7 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2025.